This is a very important aspect to consider because several drugs employed in the treatment of heart failure are P-gp substrates; therefore, the actual drug concentration is lower than expected when P-gp is over expressed, thus reducing bioavailability, since P-gp is localized between blood and cardiomyocytes (Table 1) [16,17]. Here, PGP is linked to heart failure.